Presentation is loading. Please wait.

Presentation is loading. Please wait.

CMS and FDA’s Regulatory Review & Coverage Coordination

Published byReynold Bell Modified over 8 years ago

Similar presentations

Presentation on theme: "CMS and FDA’s Regulatory Review & Coverage Coordination"— Presentation transcript:

1 CMS and FDA’s Regulatory Review & Coverage Coordination
Rochelle Fink, M.D., J.D.– FDA-CMS Liaison Center for Devices & Radiological Health U.S. Food and Drug Administration

2 Parallel Review Program
Purpose: Reduce the time between FDA marketing approval and a CMS national coverage determination (NCD) First announced: 75 Fed. Reg (Sept. 17, 2010) Described: 76 Fed. Reg (Oct. 11, 2011) Extended: 78 Fed. Reg (Dec. 18, 2013)

3 Before Parallel Review
Steps in series Coverage considered after FDA regulatory decision Payment Regulatory Concept Patients FDA decision CMS decision Now – Series. Reimbursement considered late. Long gap between FDA decision and patient access. Future – Parallel. Reimbursement considered early. Shorter (or no) gap between FDA decision and patient access. Manufacturers are encouraged to engage FDA early in the development process, sometimes well before a regulatory submission is filed.

4 Concept of Parallel Review
Steps in parallel or simultaneous Coverage considered earlier Payment Regulatory Concept Patients Payer decision FDA decision Now – Series. Reimbursement considered late. Long gap between FDA decision and patient access. Future – Parallel. Reimbursement considered early. Shorter (or no) gap between FDA decision and patient access. Manufacturers are encouraged to engage FDA early in the development process, sometimes well before a regulatory submission is filed.

5 What are we talking about?
FDA is not talking about coverage or payment but rather about communication of the evidentiary requirements from 3rd party payers to sponsors

6 Program Candidates Sponsor candidate has had sufficient pre-IDE interaction with FDA or approved IDE application Technology for which an original or supplemental application for PMA or petition for de novo review would be required Technologies that fall within a defined benefit category—Sec of the Social Security Act

7 Pilot Success Cologuard August 11, 2014: FDA approves Cologuard
CMS issues its proposed NCD October 9, 2014: CMS issued its final NCD

8 Program’s Future Payer Provide a process to enable manufacturers to include and engage payers during meetings with FDA using the Pre-Submission program FDA Review Team Manufacturer Like an advisory panel meeting.

9 What is FDA not doing? Being coverage or payment experts
Promoting specific devices or manufacturers Promoting specific payers or specific codes Considering payment or costs for approvals Modifying FDA review or decision processes Suggesting that payers use FDA’s evidentiary requirements or alter anyone’s standards

10 Important Clarifications
FDA evaluates safety and effectiveness in the same way using the same methods FDA’s communication facilitation will be done through FDA’s established Pre-Submission process Manufacturers will opt-in Manufacturers will invite payers/providers

11 Value to Stakeholders Patient
Earlier access to innovative technologies Payers Learn more about new technologies beyond current horizon scanning Provide suggestions about what data and analyses would be useful for evaluation Learn more about FDA review process

12 Value to Stakeholders Manufacturer
Engage payers earlier in discussion about evidentiary needs Potential for earlier payment due to earlier engagement FDA Improve public health by shortening the time for patients to access innovative medical devices

13 More Information Internet Information: 1) Payer Communication Task Force lproductsandtobacco/cdrh/cdrhinnovation/ucm htm 2) Pre-Submission Program Guidance ationandguidance/guidancedocuments/ucm pdf

14 Thank You

Download ppt "CMS and FDA’s Regulatory Review & Coverage Coordination"

Similar presentations

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.
Regulatory Pathway for Platform Technologies

Regulatory Pathway for Platform Technologies
Determining the Regulatory Pathway to Market Classification Heather S. Rosecrans Director, 510(k) Staff Office of Device Evaluation Center for Devices.

"Determining the Regulatory Pathway to Market" Classification Heather S. Rosecrans Director, 510(k) Staff Office of Device Evaluation Center for Devices.
Strengthening the Medical Device Clinical Trial Enterprise

Strengthening the Medical Device Clinical Trial Enterprise
510k Submission Overview Myraqa, Inc. August 22, 2012.

510k Submission Overview Myraqa, Inc. August 22, 2012.
1 FDA Update - CDRH Markham C. Luke, MD PhD Deputy Director for Clinical Office of Device Evaluation, CDRH, FDA May 15, 2012 NORD Corporate Council.

1 FDA Update - CDRH Markham C. Luke, MD PhD Deputy Director for Clinical Office of Device Evaluation, CDRH, FDA May 15, 2012 NORD Corporate Council.
Medical Device User Fee Reauthorization & FDA Update Roadmap to a Successful 510(K) Submission For Your Medical Device August 22, 2012.

Medical Device User Fee Reauthorization & FDA Update Roadmap to a Successful 510(K) Submission For Your Medical Device August 22, 2012.
Introduction to Regulation

Introduction to Regulation
FSMA: Where We’ve Been and Where We’re Going Supplemental Notices of Proposed Rulemaking Public Meeting November 13, 2014 Roberta F. Wagner, B.S., M.S.

FSMA: Where We’ve Been and Where We’re Going Supplemental Notices of Proposed Rulemaking Public Meeting November 13, 2014 Roberta F. Wagner, B.S., M.S.
Medical Devices Approval Process

Medical Devices Approval Process
+ Medical Devices Approval Process. + Objectives Define a medical device Be familiar with the classification system for medical devices Understand the.

+ Medical Devices Approval Process. + Objectives Define a medical device Be familiar with the classification system for medical devices Understand the.
Mrs. Brandi Robinson Office of New Animal Drug Evaluation Center for Veterinary Medicine Regulating Animal Drugs.

Mrs. Brandi Robinson Office of New Animal Drug Evaluation Center for Veterinary Medicine Regulating Animal Drugs.
1 1 PDUFA & FDA Legislation FDA Regulatory & Compliance Symposium August 2006 Marc Wilenzick, Moderator for Panel: Dan Carpenter, Harvard Dept. of Government.

1 1 PDUFA & FDA Legislation FDA Regulatory & Compliance Symposium August 2006 Marc Wilenzick, Moderator for Panel: Dan Carpenter, Harvard Dept. of Government.
1 ACPS November 15, 2000 314.70 Update Nancy B. Sager, Associate Director Office of Pharmaceutical Science Center for Drug Evaluation & Research Food and.

1 ACPS November 15, Update Nancy B. Sager, Associate Director Office of Pharmaceutical Science Center for Drug Evaluation & Research Food and.
FDA Resources and Meetings FDA/EMA Orphan Designation and Grant Workshop Silver Spring, Maryland FDA Campus (White Oak) October 12, 2012 Bill Sutton Deputy.

FDA Resources and Meetings FDA/EMA Orphan Designation and Grant Workshop Silver Spring, Maryland FDA Campus (White Oak) October 12, 2012 Bill Sutton Deputy.
The Changing Food Environment The Role and Activities of the U.S. Food and Drug Administration Transatlantic Consumer Dialogue The Changing Food Environment.

The Changing Food Environment The Role and Activities of the U.S. Food and Drug Administration Transatlantic Consumer Dialogue The Changing Food Environment.
1 Regulatory Concepts for Dual Indication Combination Products Charu Mullick, M.D. Division of Antiviral Products, CDER U.S. Food and Drug Administration.

1 Regulatory Concepts for Dual Indication Combination Products Charu Mullick, M.D. Division of Antiviral Products, CDER U.S. Food and Drug Administration.
Andrew Gettinger, MD, FCCP, FCCM CMIO, Office of the National Coordinator for HIT Director (acting), Office of Clinical Quality and Safety Health IT Safety.

Andrew Gettinger, MD, FCCP, FCCM CMIO, Office of the National Coordinator for HIT Director (acting), Office of Clinical Quality and Safety Health IT Safety.
Understanding the Pre-IDE Program: FDA Perspective

Understanding the Pre-IDE Program: FDA Perspective
FDA Science Board Drug Safety Initiative April 15, 2005 Rockville, MD RADM Steven Galson, MD, MPH Acting Director, Center for Drug Evaluation and Research.

FDA Science Board Drug Safety Initiative April 15, 2005 Rockville, MD RADM Steven Galson, MD, MPH Acting Director, Center for Drug Evaluation and Research.

Similar presentations

Ads by Google